Status:
COMPLETED
Effects of Azithromycin on Airway Oxidative Stress Markers in Patients With Bronchiectasis
Lead Sponsor:
Instituto de Investigacion Sanitaria La Fe
Collaborating Sponsors:
Sociedad Valenciana de Neumología
Conditions:
Bronchiectasis
Eligibility:
All Genders
16-80 years
Phase:
NA
Brief Summary
The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established. In the present work, the investigators will analyz...
Detailed Description
The mechanism by which macrolide antibiotics have immune modifying effects independent from its antibacterial activity has not been well established. In the present work, we will analyze the effect of...
Eligibility Criteria
Inclusion
- Previous diagnosis of bronchiectasis based on lung HRCT and clinical symptoms
- Clinically stable in previous four weeks without exacerbations
- Informed consent
Exclusion
- Bronchiectasis secondary to Cystic fibrosis, pulmonary surgical processes, immune deficiency, emphysema, allergic bronchopulmonary aspergillosis or diffuse interstitial pulmonary diseases
- Intolerance to macrolides or severe liver disease.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01463371
Start Date
October 1 2006
End Date
September 1 2007
Last Update
September 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital La Fe
Valencia, Spain, 46026